DAta-driven personaLIzation of a digitAl Health Solution to Support Family Caregivers of Children With Chronic Conditions

Status: Recruiting
Location: See location...
Intervention Type: Combination product
Study Type: Observational
SUMMARY

The goal of this feasibility study is to explore the needs of families with children with obesity and evaluate the impact of a combined intervention (children with obesity receiving pharmacological therapy in combination with the Adhera Caring Digital Program®) on treatment satisfaction, adherence, and mood. The main objectives are: * To evaluate the impact of the treatment combination (ACDP® and pharmacological treatment) in terms of satisfaction, engagement, adherence and mood, in families with children with obesity. * To better understand the educational and support needs of the families of children with obesity while under treatment and lifestyle changes. Participants will: * Use the Adhera Caring Digital Program® (ACDP®) for obesity, which includes digital therapeutic software, personalized messages, and educational materials. * Take pharmacological treatment as prescribed for one year. * Wear activity wristbands/watches to collect biometric data. * Attend monthly clinic visits for assessments and monitoring. * Complete psychometric questionnaires to measure satisfaction, adherence, and emotional outcomes. * Engage in chat-based communication and video conferencing with health coaches for support and monitoring.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Caregivers of children between 13 and 18 years who are diagnosed with obesity and undergoing treatment according to the approved label by AEMPS1 (adolescents with obesity aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex).

• Families of children with obesity who have been under pharmacological treatment before screening. This includes treatment with any of the following medications orlistat, metformin, liraglutide, semaglutide.

• Participants who are willing to join ACDP® for 10 months and can interact with a smartphone during that time.

• The family is willing to complement the pharmacological obesity treatment with a digital intervention.

• Participants (patients and their caregivers) must be willing to use wearables for the entire length of the study.

• Parents previously using a wearable will agree not to use it during the length of the study, as their wearable account must be synched to the patient's device. Further, they may need to agree on changing the account data for height, weight, and gender in their Google account.

Locations
Other Locations
Spain
Hospital Universitario Miguel Servet
RECRUITING
Zaragoza
Contact Information
Primary
Luis Fernadez-Luque, Dr
luis@adherahealth.com
+34 656930901
Time Frame
Start Date: 2025-03-11
Estimated Completion Date: 2026-05
Participants
Target number of participants: 40
Treatments
Cohort
40 families with children already receiving pharmacological therapy as per clinical indication will be asked to use the ACDP® for obesity. We will track their progress with the digital intervention for ten months, and there will be a 2-month follow-up (total 12 months)
Related Therapeutic Areas
Sponsors
Collaborators: Hospital Universitario Miguel Servet, Zaragoza, University of Seville, University of Valencia
Leads: Adhera Health, Inc.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials